Christopher Ryan Sullivan, the chief financial officer of Avalo Therapeutics, Inc. (NASDAQ:AVTX), sold a total of 16,059 shares of the company’s common stock over two days - April 1 and April 2, 2026 - according to a recent SEC Form 4 filing. The disposition was carried out under a pre-arranged 10b5-1 trading plan and generated $270,593 in aggregate proceeds.
The breakdown of the April 1 activity shows two separate blocks: 500 shares were sold at a weighted average price of $15.858, with individual transaction prices ranging from $15.24 to $16.21; and 7,479 shares were sold at a weighted average price of $16.8259, with execution prices between $16.45 and $17.38. On April 2, Sullivan sold 6,200 shares at a weighted average price of $17.0247, in a range of $16.385 to $17.37, and an additional 1,780 shares at a weighted average price of $17.5674, with prices between $17.39 and $17.80.
Following these sales, Sullivan directly holds 17,338 shares of Avalo Therapeutics. The filing specifies that the transactions were executed pursuant to the 10b5-1 plan, indicating the trades were scheduled under pre-established parameters.
The stock has experienced notable upward momentum. Over the past 12 months, Avalo shares have increased approximately 170 percent, and they rose about 28 percent in the week leading up to these transactions. The share price at the time of reporting is $17.76. An InvestingPro analysis referenced in the filing material indicates the shares may be overvalued at current levels and points investors to detailed valuation metrics and additional InvestingPro tips for AVTX.
Analyst coverage and commentary cited in the filing and related disclosures remain broadly favorable. H.C. Wainwright raised its price target on Avalo to $40 and retained a Buy rating, citing increased confidence in the company’s AVTX-009 candidate for hidradenitis suppurativa. BTIG reiterated a Buy rating with a $40 price objective while emphasizing the market’s focus on expected Phase 2 data in the second quarter of 2026. Guggenheim is reported to have maintained a Buy rating and set a $50 price target following Avalo’s fiscal 2025 earnings announcement, noting that the Phase II LOTUS study is on track. TD Cowen also reiterated a Buy rating, highlighting the potential opportunities tied to the Phase II trial. Additionally, Guggenheim is noted as having initiated coverage with a Buy rating and a $50 price target, expressing optimism about the company’s IL-1beta inhibitor AVTX-009 and its potential competitive advantages.
These analyst actions underline continued market attention on Avalo’s clinical programs and upcoming readouts. The SEC Form 4 filing documents the insider sales and the remaining share ownership; it does not provide further commentary on timing or motivation beyond the use of the 10b5-1 plan.
Summary
The CFO of Avalo Therapeutics sold 16,059 shares on April 1 and 2, 2026 under a 10b5-1 plan, receiving $270,593. The company’s stock has climbed sharply over the prior year and the most recent week, and several analysts hold Buy ratings with price targets ranging from $40 to $50 in relation to AVTX-009 and upcoming Phase II data.